Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Im suprised theres not more people adding shares at .0009 with the resistance at 8 and how thin the ask is...Ive added a few mill at .0009
L2 looks good, 3 mms at 8, 2 at 7 on the bid
ask is 1 mm at 9, 1 at 1, 2 at 11
buys at ask, ask moving up...
Im buying at 2, seems like a good time to buy.
We need some buying at the ask here!
I really dont understand why people would be selling at the bid.
I feel as if a lot of people bought in on the news and are now trying to dump their shares cause the real investors wouldnt be dumping shares this low.
Jesus, what is going on with this stock?
dont understand why its dropping so much.
Whens the bleeding going to stop
Good traders are buying shares right now whereas the bad traders are dumping instead of averaging down
I think im going to jump in this one...looks ready for a breakout!
GLA
way undervalues here, lots of volume in the am, just picked up shares at 40
does anyone use their software?
i may try it out for 30/month
does it have a streaming news feed like equityfeed?
NEW JERSEY EXPECTED TO LEGALIZE MARIJAUNA SOON!
New Jersey, outgoing Gov. Corzine expected to legalize medical marijuana
BY Bill Hutchinson
DAILY NEWS STAFF WRITER
Tuesday, January 12th 2010, 4:00 AM
Marijuana buds confiscated by law enforcement officers.
Holland/AP
Marijuana buds confiscated by law enforcement officers.
Take our Poll
Medical marijuana
How do you feel about medical marijuana?
It should be legal in every state in the nation.
It should not be legal in any state in the nation.
It's legal in 14 states right now - let's leave it at that.
Not sure. It's too complicated an issue.
Related News
* Articles
* Editorial: Got it right, did it wrong
* Fed probe of Lottery not tied to Aqueduct bid: gov aide
* Obama now says he's 'agnostic' on hiking taxes for families below $250K annual income
* Charlie Wilson, who helped Afghans fight Soviets, dies
* US attorney's office subpoena's Senate in probe of Senate President Malcolm Smith
* Biden: Another 9/11-like attack is 'unlikely'
*
The Garden State is set to bloom with weed.
Outgoing Gov. Jon Corzine is expected to sign legislation before leaving office next week making New Jersey the nation's 14th state to legalize medical marijuana.
Legislators approved a law Monday allowing chronically ill patients to buy up to 2 ounces of pot a month at state-monitored dispensaries.
"I don't think we should make criminals out of our very sick and terminally ill," said Assemblyman Reed Gusciora (D-Princeton), co-sponsor of the bill.
Corzine, who supports the legislation, is expected to sign it into law before turning over power to incoming Republican Gov. Chris Christie, a former federal prosecutor who has voiced concerns over the bill.
The law authorizes the state Department of Health to issue patients with "debilitating medical conditions" like cancer or AIDS the right to legally possess marijuana.
Unlike other states where medical marijuana is legalized, patients will not be allowed to grow their own.
Medical Marijuana Inc Announces Sale of 1st State License
14 minutes ago - Marketwire
Related Companies
Symbol Last %Chg
MJNA 0.21 0.00%
As of 12:39 PM ET 2/11/10
Medical Marijuana Inc (PINKSHEETS: MJNA) proudly announced today it has sold its first joint venture interest for the State of Nevada for $100,000. This contract is for the Medical Marijuana Institute of Nevada to be our partner in all events that take place in Nevada. As the state licensee, this contract permits this licensee to set up joint ventures statewide with other participants to promote MJNA educational events. The first Educational Symposium is set for Las Vegas, Nevada on March 20th and 21st. Numerous other events are being planned for cities all over Nevada as city partners joint venturing with the state licensee firm up their city agreements. Tickets can be purchased online at: http://medicalmarijuanainc.com. This indicates significant revenue projections for MJNA in this newly launched division of the company as there are now over 50 inquires for other joint venture partners coming in from all over the country.
Medical Marijuana Inc's Educational Symposiums are a multifaceted approach designed to educate anyone interested in entering this emerging multibillion dollar industry. MJNA also offers Turnkey Management Solutions, as well as ala carte items, such as the sale of products and services that can be resold through partners, including their revolutionary patent pending tax remittance card which can pay taxes on retail sales of medical cannabis on a daily basis creating an economic windfall for city and state governments utilizing this system.
Medical Marijuana Inc's Educational Symposiums provide education on topics that include the history of cannabis, cutting edge cultivation, current laws and ordinances, therapeutic uses, caregiver requirements, establishing dispensaries and operations, and a vast array of business protocols. One can sign up for our upcoming Educational Symposiums via our website: www.medicalmarijuanaeducationalexpo.com.
Bruce Perlowin, CEO of Medical Marijuana Inc, said, "This new business opportunity for the medical marijuana industry has created a huge ground swell of entrepreneurs wanting to get into this area of the industry, as we have now provided a ground breaking income opportunity marketing something more important than medical marijuana itself -- education and information on every aspect of this emerging multibillion industry."
For those interested in entering into a licensing agreement with us, please contact us at centers@medicalmarijuanainc.com, or come to one of our upcoming events to see how they are run and the incredible energy and amazing speakers we feature at these events.
SOLUTIONS
Medical Marijuana Inc has developed a suite of solutions to deliver an efficient and secure infrastructure for the Medical Marijuana Industry which provides the tools to industry operators to effectively manage their business with the confidence they are in full compliance with all local, state and federal laws.
MEDICAL MARIJUANA INC'S TURNKEY COLLECTIVE SOLUTION
Medical Marijuana Inc's Turnkey Collective Solution ensures that collectives operate within the guidelines of all laws and regulations regarding the tracking of the cannabis from grow cycle to final distribution. By employing Medical Marijuana Inc's closed loop tracking system, it can be shown to authorities and collectives alike that the source of their supply was an active member of the collective and complying with all current laws.
TAX COLLECTION
The Stored Value Platform System provides verifiable solutions to manage the difficult task of revenue and taxation collection. The customers of the dispensary are issued a plastic debit card or medical revenue card. The ease of access to certifiably secure transactions lessens the risk of loss at each level of the transaction.
ABOUT MEDICAL MARIJUANA INC
Medical Marijuana Inc recognizes the vast and unequaled opportunities that exist in the rapidly expanding medical marijuana industry. The scientific recognition of cannabis has brought legalized marijuana use to the forefront of mainstream discussion thus opening the door for safe and lucrative investment opportunities.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana Inc to be materially different from the statements made herein.
SOURCE: Medical Marijuana Inc
RECORD VOLUME 1MM left at .0002, hurry and get .0002s while you can
this is gonnna fly tomorrow. record volume
Huge potential here
Medical Marijuana Inc Announces Sale of Nevada License Market Wire "US Press Releases "
LOS ANGELES, CA -- (MARKET WIRE) -- 02/10/10 -- Medical Marijuana Inc (PINKSHEETS: MJNA) proudly announced today it has sold its first partnership in Nevada for $100,000 . This contract is for the Medical Marijuana Institute of Nevada to be our partner in the Educational Symposium being planned now in Las Vegas, Nevada on March 20th and 21st. Tickets can be purchased online at: http://medicalmarijuanainc.com.
Medical Marijuana Inc's Educational Symposiums are a multifaceted approach designed to educate anyone interested in entering this emerging multibillion dollar industry. MJNA also offers a complete menu of services including Turnkey Management Solutions, including products and services that can be resold through partners that team up with us to hold these Educational Symposiums throughout the country.
Medical Marijuana Inc's Educational Symposiums provide education on topics that include the history of cannabis, cutting edge cultivation, current laws and ordinances, therapeutic uses, caregiver requirements, establishing dispensaries and operations, and a vast array of business protocols. One can sign up for our upcoming Educational Symposiums via our web sites: www.medicalmarijuanainc.com and www.medicalmarijuanaeducationalexpo.com.
Bruce Perlowin - CEO of Medical Marijuana Inc , said, "This new business opportunity for the medical marijuana industry has created a huge ground swell of entrepreneurs wanting to get into this area of the industry."
For those interested in entering into a licensing agreement with us, please contact us at center@medicalmarijuanainc.com, or come to one of our upcoming events to see how they are run and the incredible energy and amazing speakers we feature at these events.
SOLUTIONS
Medical Marijuana Inc has developed a suite of solutions to deliver an efficient and secure infrastructure for the Medical Marijuana Industry which provides the tools to industry operators to effectively manage their business with the confidence they are in full compliance.
MEDICAL MARIJUANA INC'S TURNKEY COLLECTIVE SOLUTION
Medical Marijuana Inc's Turnkey Collective Solution ensures that collectives operate within the guidelines of all laws and regulations regarding the tracking of the cannabis from grow cycle to final distribution. By employing Medical Marijuana Inc's closed loop tracking system, it can be shown to authorities and collectives alike that the source of their supply was an active member of the collective.
TAX COLLECTION
The Stored Value Platform System provides verifiable solutions to manage the difficult task of revenue and taxation collection. The customers of the dispensary are issued a plastic debit card or medical revenue card. The ease of access to certifiably secure transactions lessens the risk of loss at each level of the transaction.
ABOUT MEDICAL MARIJUANA INC
Medical Marijuana Inc recognizes the vast and unequaled opportunities that exist in the rapidly expanding medical marijuana industry. The scientific recognition of cannabis has brought legalized marijuana use to the forefront of mainstream discussion thus opening the door for safe and lucrative investment opportunities.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana Inc to be materially different from the statements made herein.
Health Discovery and New York City Pancreatic Cancer Center form partnership
Posted on: Tue, 09 Feb 2010 08:02:14 EST
Symbols: HDVY
Are you looking to increase your ETF knowledge?
See the PowerRating of HDVY now and learn how it rates on a 1-10 scale.The higher the PowerRating, the greater potential short-term gain based on historical data.
Feb 09, 2010 (Datamonitor via COMTEX) --
Health Discovery, a molecular diagnostics company, has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to develop new molecular diagnostic tests for the early detection of pancreatic cancer.
The Pancreas, Biliary and Liver Surgery Center is under the leadership of Michael Wayne, Franklin Kassim and Avram Cooperman.
Under the terms of the agreement, the Pancreas, Biliary and Liver Surgery Center will provide all specimens from their collected specimen banks, specimens on all new patients and all associated clinical and outcomes data.
The specimens will include tissue, blood and urine. Health Discovery will use its patent protected SVM-based discovery technology and expert science team to develop these new molecular diagnostic tests for pancreatic cancer in a similar fashion to the urine-based prostate cancer test developed by the company and licensed for development and commercialization to Quest Diagnostics and Abbott on a royalty-based, world-wide co-exclusive basis.
Health Discovery will own all of the intellectual property and commercialization rights to these newly discovered molecular diagnostic tests for pancreatic cancer and the company intends to immediately partner with a large clinical laboratory for development, marketing and commercialization of these tests.
Stephen Barnhill, chairman and CEO of Health Discovery, said: "We are very excited to partner with Dr Wayne, Dr Kassim and Dr Cooperman and their colleagues, all experts in pancreatic cancer, to work together in the development of new molecular diagnostic tests for the early detection of pancreatic cancer. The specimen bank established by these doctors provides a rare opportunity to accomplish this vital goal."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on (HDVY) HDVY. (HDVY) has Short Term PowerRatings at TradingMarkets. Details on (HDVY) Short Term PowerRatings is available at This Link.
More News: Market Updates | Stock Alerts | All Trading News
I agree...cant believe no one has touched the ask
good news!
$2? there is no way itll hit that . sorry. maybe 1 dollar tho
this thing is going to fly! 510k approval 6-month review estimate is 2/7
plans to delist from nasdaq . . damn
closed HOD . id watch out
looking good
hopefully this will be seeing some action soon . i got in at .42 on friday and somehow it closed at .60
BMR alerted DSCI friday to the public so monday should be a volume spike
------------------------
Derma Sciences (OTC:DSCI): Unique Opportunity in Advancing Wound Care
Written by Mike Havrilla
Friday, 28 August 2009 12:11
Derma Sciences presents a unique opportunity in the micro-cap biomed space. The company is developing a patented topical drug for accelerated healing and scar prevention and newly launched Advanced Wound Care products approaching $10M, including the highly received MEDIHONEY® dressings at greater than 70% gross margin.
The presentation highlights the following about Derma Sciences: (1) new Advanced Wound Care Products are selling at a current run rate approaching $10 million in revenue, including total annualized MEDIHONEY revenues in excess of $3.5 million with a gross margin of 70%; (2) total revenues are expected to exceed $50 million in 2009 including sales from the introduction of four new advanced wound care products since 4Q08; and (3) an enterprise value for the Company that is about 0.5X trailing 12-month sales despite its recently launched wound dressing product, a strong novel pharmaceutical candidate for wound healing in Phase 2 development (at an estimated expense of $1.7M), and $3.5 million dollars in core business EBITDA to help support future growth/R&D initiatives.
As of its corporate presentation dated 8/21/09, Derma Sciences reported that it continues to move forward with a Phase 2 clinical trial of DSC127, which has the potential to be only the second approved drug on the market for accelerated wound healing. The Company stated that 33% of patients are currently enrolled in a Phase 2 diabetic foot ulcer study. DSC127 (which is an analog of a naturally occurring peptide called Angiotensin that has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization) was licensed from the University of Southern California during 4Q07 and patient enrollment for a Phase 2 study began during 4Q08.
This study of 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period in addition to other outcomes. Histological examination reveals that DSC127 accelerates collagen deposition six-fold and the patented amino acid peptide optimizes the wound healing capabilities of Angiotensin while removing all blood pressure effects of the compound. The Phase II results for the DSC127 Diabetic Ulcer trial are scheduled for release during early 3Q10, with an estimated date for this entry of 7/31/10.
Systagenix, which is a division of Johnson & Johnson (NYSE:JNJ), currently markets Regranex as the only FDA-approved treatment for wound healing with annual sales of about $100M. However, this product carries a black box warning that states, "An increased risk of mortality secondary to malignancy was observed in patients treated with three or more tubes of Regranex Gel in a post-marketing retrospective cohort study. . . should be used with caution in patients with known malignancy." In addition, DSC127 has been shown in pre-clinical animal studies to be more effective than Regranex and Shire (NASDAQ:SHPGY) licensed the rights to a scar prevention drug (Juvista or Human TGFbeta3) from UK-based Renovo (LON:RNVO) (ROVOF.PK) in June 2007 which was in late Phase 2 development at the time (now in Phase 3 trials) in a deal that included $75M in up-front cash, milestone-related payments that could total approximately 10X the up-front payment, and future sales royalties if approved for marketing.
Derma Sciences reported that gross U.S. MEDIHONEY sales increased by 125% and 94% to $664,766 and $1.14 million (M) during 2Q09 and 1H09, respectively, compared to the year-ago periods. The Company also announced record first-month sales of $58,458 for BIOGUARD, which was launched in late June and represents a new anti-microbial advanced wound care product. Gross sales of key new advanced wound care products in the U.S. increased by 93% during 1H09 to a level of $2.14M versus $1.1M in the year-ago period.
On 7/27/09, the Company announced that a paper published in the European Journal of Clinical Microbiological Infectious Diseases details how a certain kind of honey can be an effective agent in topical wound care, particularly where antibiotic resistance is an issue. The report describes the palliative effects of Leptospermum honey, which contains unique plant-derived components that make it an ideal wound dressing with favorable properties that include low pH levels, the ability to help remove non-vital tissue from the wound area, stimulate new tissue growth, and reported reduction in scarring and pain levels. This study adds to a growing base of scientific literature for medicinal honey and wound care, including 15 peer-review published journal articles and 25 clinical posters or abstracts presented at major wound care conferences since the Company launched MEDIHONEY.
The paper concluded that honey is an effective topical antimicrobial agent that could help reduce some of the current pressures that are promoting antibiotic resistance. Derma Sciences has strong IP (intellectual property, patents) around dressing configurations that include honey, exclusive rights for MEDIHONEY in the Americas (with the expectation of obtaining worldwide rights by the end of 2009), and a partnership with New Zealand-based Comvita, which controls 75% of the Leptospermum honey harvested. MEDIHONEY dressings, a unique line of products containing active Leptospermum honey, provide a moist, occlusive environment conducive to optimal wound healing, enabling them to work effectively in the presence of wound fluid, blood, and tissue, promoting an optimal healing environment.
BIOGUARD Barrier Dressings provide a barrier to bacterial contamination while also providing greater than 5-log (99.999%) average reductions of common pathogens within the dressings with a distinguishing feature that includes the ability to function even in the presence of wound fluid and blood. The active component of the dressings is a non-toxic polymer (p-DADMAC) that is patented for use in wound dressings and licensed on an exclusive basis since 2007 from Quick-Med Technologies (QMDT.OB). Also, the active component is non-leaching, which is an important feature since leaching antimicrobials can interfere with wound healing and lead to the development of resistant strains of microbial pathogens.
Overall net sales came in at $11.6M and $22M during 2Q09 and 1H09, respectively, compared to $13.1M and $24.8M in the year-ago periods. The revenue decline was principally driven by lower sales from the First Aid Division, which the Company attributed to a weakening of the economy and a decrease in Canadian net sales attributable to unfavorable foreign currency exchange and inventory rationalization on the part of its exclusive Canadian distributor. During 1H09, the majority of the Company's sales occurred in the U.S. market (73%) with 22% of sales occurring in Canada. However, the Company noted that despite the sales decline for the First Aid division, gross margins for this segment have improved during 2009.
The Company's gross profit margin increased to 29.6% and 30.8% during 2Q09 and 1H09, respectively, as compared to 27% and 26.9% in the year-ago periods. Derma attributed the increase in gross profit margin to cost-effective manufacturing for its First Aid division combined with growth in its higher margin advanced wound care business. Selling, general, and administrative expenses decreased by 17.4% and 14% during 2Q09 and 1H09, respectively, compared to the year-ago periods.
Derma Sciences posted a net loss of $560,502 or ($0.01/share) and $1.3M or ($0.03/share) during 2Q09 and 1H09, respectively, as compared to the year-ago periods. The Company's posted an impressive improvement in its overall cash flow during 1H09 as it generated positive cash flow from operating activities of $198,492 as compared to the use of $5.26M in cash from operating activities in the year-ago period. The Company ended 2Q09 with about 40.3M shares of common stock outstanding, $167,040 in unrestricted cash + equivalents, $11.5M of inventories, restricted cash of $2M (reflecting the amended credit and security agreement with use subject to approval by the lender), accounts receivable of $3.2M, total current liabilities of $9.2M (including $3.8M in amended line of credit borrowings and $2.6M in accounts payable), and long-term debt of $2.9M.
As of 6/30/09, the Company had warrants outstanding to purchase 8.8M shares of its common stock at a weighted average price of about $0.98 over a period of five expiration dates ranging from April 2011 to March 2014. In addition, Derma Sciences has 9.4M options outstanding and 6.6M which are exercisable at the end of 2Q09 with average exercise prices of $0.63 and $0.68, respectively. The Company had a total of 25.1M shares of common stock shares reserved as of 6/30/09, which include the warrants and options outlined above in addition to convertible preferred shares and restricted common stock.
The Company consists of the following three operating segments: wound care, wound closure and specialty securement devices and skin care. Products in the wound care segment account for about 94% of total net sales and 91.4% of gross profits through 1H09 and this division consists of basic + advanced dressings, adhesive strips, ointments, and sprays. Wound closure and specialty securement device products include wound closure strips, nasal tube fasteners, and a variety of catheter fasteners while the skin care segment consists of antibacterial skin cleansers, hair and body soaps, lotions, and moisturizers.
Derma Sciences has an impressive track record with regard to insider ownership and open market buying and as of the Company's 8/21/09 corporate presentation there is 17% insider + 63% institutional ownership of the outstanding shares of common stock. Excluding the recent option grants at a zero cost basis on 6/1/09 for a total of 150,000 shares; insiders have purchased 228,100 shares of common stock since 12/3/07 at a weighted average cost basis of $0.56/share, which represents a 36.5% premium to the closing stock price on 8/27/09 of $0.41/share.
Derma Sciences presents a unique opportunity in the micro-cap biomed space since it has a core business focused on would care which generates revenue and operating cash flow to fund the Phase 2 clinical development for a treatment (DC127) that targets a prescription drug market that is about 5X the Company's current market cap (based on Regranex sales of $100M). In addition, pre-clinical data suggests DC127 may offer both safety and efficacy advantages over Regranex and the licensing deal by Shire for a scar prevention treatment that included a $75M up-front payment suggests Derma Sciences has the potential to secure a licensing deal that could include an up-front cash payment in excess of its current market cap of around $20M.